Cipla

Cipla
From Wikipedia, the free encyclopedia
CIPLA Limited
Type Public (BSE: 500087)
Industry Pharmaceuticals
Founded 1935
Headquarters Mumbai, India
Key people Y. K. Hamied (CMD), Chairman
Products Pharmaceuticals and diagnostics
Revenue ▲ 5,624.91 crore (US$1.22 billion)(2010)[1]
Net income ▲ 1,082.59 crore (US$234.92 million)(2010)
Employees over 7,000
Website www.cipla.com
Cipla, (BSE: 500087) is a prominent Indian pharmaceutical company, best-known outside its home country

for manufacturing low-cost anti-AIDS drugs for HIV-positive patients in developing countries. Founded
by Khwaja Abdul Hamied as The Chemical, Industrial & Pharmaceutical Laboratories in 1935, Cipla
makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other
health conditions, and its products are distributed in more than 180 countries worldwide. [2]
Contents
[hide]
1 Technology services
2 HIV/AIDS in the developing
world
3 2007 AHF campaign
4 Antiflu and Virenza
5 Other drugs
6 See also
7 References
8 External links
[edit]Technology services
Cipla offers services like consulting, commissioning, engineering, project appraisal, quality control, know-
how transfer, support, and plant supply.
Apart from its presence in the Indian market, Cipla also has an export market and regularly exports to more
than 150 countries in regions such as North America, South American, Asia, Europe, Middle East,
Australia, and Africa. For the year ended 31 March 2007 Cipla’s exports were worth approximately Rs.
17,500 million. Cipla is also considerably well-known for its technological innovation and processes for
which the company received know-how royalties to the tune of Rs. 750 million during 2006-07 [citation needed].
Cipla has been approved by regulatory bodies such as:
 World Health Organization
 Food and Drug Administration (FDA), USA
 Therapeutic Goods Administration (TGA), Australia
 Pharmaceutical Inspection Convention (PIC), Germany
 National Institute of Pharmacy (NIP), Hungary
 The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency
Cipla has recently launched i-Pill which is a single dose emergency contraceptive and has acquired a great
deal of popularity in a short span of time. Other latest launches of Cipla include products such as Nova,
Moxicip, Flomex, Fullform, Montair LC, and Imicrit.
[edit]HIV/AIDS in the developing world
Today (2007), Cipla is the world's largest manufacturer of antiretroviral drugs[3] (ARVs) to fight HIV/AIDS,

as measured by units produced and distributed (multinational brand-name drugs are much more
expensive, so in money terms Cipla medicines are probably somewhere down the list). Roughly 40 percent
of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs. [4][5]
Indian law from 1972 until 2005 allowed no (end-product) patents on drugs, and provided for compulsory
licensing, Cipla was able to manufacture medicines which enjoyed patentmonopoly in certain other
countries (particularly those where large, multinational pharmaceutical companies are based). By doing so,
as well as by making an executive decision not to make profits on AIDS medication, Cipla reduced the cost
of providing antiretrovirals to AIDS patients from $12,000 and beyond (monopoly prices charged by
international pharma conglomerates) down to around $300 per year. Today they are able to do so for under
$150 per patient per year. While this sum remains out of reach for many millions of people in Third
World countries, government and charitable sources often are in a position to make up the difference for
destitute patients. However, in producing generic versions of drugs which are patent-protected, the
company has provoked the ire of the pharmaceutical companies which own the patents. [6][7] Whilst Cipla
has argued that the ethics of humanitarian relief should outweigh Intellectual property considerations,
brand-name pharmaceutical companies have countered that high prices are vital to offset high Research
and development costs (though typically such companies spend far more on marketing and administration
than they do on research[citation needed]).
Cipla developed a three-in-one tablet called Triomune containing a fixed-dose combination (FDC) of three

ARVs (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents
were held by different companies. Another popular fixed-dose combination is produced under the name
Duovir-N. This contains Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of
many of the most commonly prescribed anti-retroviral medication in the market, [8] and is a highly capable
manufacturer in its own right. This innovation made ARVs far more accessible and easy-to-take for patients
everywhere, but particularly in poor- and middle-income countries, where the vast majority of people on
anti-retroviral therapy (ART) now take such combination pills.
Cipla is one of the first companies to register AIDS drugs under the US program PEPFAR.[9]
[edit]2007 AHF campaign
In August 2007 Cipla was confronted by a US-based group known as AIDS Healthcare Foundation (AHF)
with a well-funded campaign of full-page ads in various Indian newspapers suggesting Cipla was pricing an
AIDS drug called Viraday higher in India than in Africa.[10]
It soon emerged that AHF was closely associated with American pharma conglomerate Gilead Sciences,
maker of a competing drug. On September 1, 2007, The Economic Times of Delhi wrote that:
It has now emerged that Aids Healthcare Foundation (AHF), the US-based NGO that accused Cipla of over
pricing anti-AIDS drug, Viraday, in India is part funded by American anti-AIDS drug maker Gilead and the
NGO's treasurer is a senior Gilead executive. This is largely the reason why foreign and Indian NGOs such
as Medicins Sans Frontieres (MSF), Delhi Network of Positive People (DNP+), Indian Network of Positive
People (INP+), Sahara and others refused to be part of AHF's anti-Cipla campaign.” [11]
[edit]Antiflu and Virenza
In December 2008, Cipla won a court case in India allowing it to manufacture a cheaper generic version
of oseltamivir, marketed by Hoffmann-La Roche (Roche) under the trade nameTamiflu, under the Cipla
tradename Antiflu. In May 2009, Cipla won approval from the World Health Organization certifying that its
drug Antiflu was as effective as Tamiflu, and Antiflu is included in the World Health Organization list of
prequalified medicinal products.[12]
Cipla announced that Oseltamivir 75 mg capsules marketed as `Antiflu` by the company has been included
in the World Health Organization (WHO) list of prequalified medicinal products (PMP).
Oseltamivir is indicated for use in the treatment of influenza A (H1N1) infection commonly known as swine
flu.
Cipla also produces a generic version of zanamivir, marketed by Glaxo under the trade name Relenza,
under the Cipla tradename Virenza.
The Saudi government has recently purchased stockpiles of Antiflu in preparation for the upcoming Hajj.[13]
The firm announced the launch of the drug under brand name: "antiflu" on November 11, 2009 to be sold
as a category X drug, strictly under prescription. The firm has already sold 2 lakh (200,000) doses to the
Indian Government.[14]
[edit]Other drugs
Cipla has a product range comprising antibiotics, anti-bacterials, anti-asthmatics, anthelmintics, anti-
ulcerants, oncology, corticosteroids, nutritional supplements and cardiovascular drugs. The company has
at least nine different prescription drugs registered with the US FDA.[15] Cipla is into anti-bacterial and anti-
asthmatic segments and is the first player in Asia to launch non-CFC metered dose inhaler.

Cipla

Uploaded by

Copyright:

Available Formats

Cipla

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Cipla

Uploaded by

Copyright:

Available Formats

Cipla

From Wikipedia, the free encyclopedia

Key people Y. K. Hamied (CMD), Chairman

Revenue ▲ 5,624.91 crore (US$1.22 billion)(2010)[1]

Net income ▲ 1,082.59 crore (US$234.92 million)(2010)

Employees over 7,000

Cipla, (BSE: 500087) is a prominent Indian pharmaceutical company, best-known outside its home country

2 HIV/AIDS in the developing

4 Antiflu and Virenza

 World Health Organization

 Food and Drug Administration (FDA), USA

 Therapeutic Goods Administration (TGA), Australia

 Pharmaceutical Inspection Convention (PIC), Germany

 National Institute of Pharmacy (NIP), Hungary

[edit]HIV/AIDS in the developing world

Today (2007), Cipla is the world's largest manufacturer of antiretroviral drugs[3] (ARVs) to fight HIV/AIDS,

Cipla developed a three-in-one tablet called Triomune containing a fixed-dose combination (FDC) of three

[edit]2007 AHF campaign

[edit]Antiflu and Virenza

You might also like